Arrowhead Pharmaceuticals Interest Expense 2011-2026 | ARWR

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Arrowhead Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5.26 M	-1.75 M	1.54 M	765 K	2.07 M	-583 K	-	7.49 K	1.31 M	57.4 K	418 K	82.1 K	-998 K	36 K	86.5 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.26 M	-1.75 M	593 K

Quarterly Interest Expense Arrowhead Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
277 K	-	-176 K	341 K	-	760 K	7.24 M	421 K	-	306 K	5.06 M	2.85 M	-	-	1.76 M	-707 K	-	664 K	-110 K	1.15 M	-	-	1.15 M	-	-	-	-	-	-	-	-	-	1.31 M	1.31 M	5.72 K	1.31 M	-	-	1.31 M	-	483 K	483 K	536 K	-53.2 K	81.3 K	10.1 K	-53.2 K	-5.33 K	-998 K	259 K	-5.33 K	22.7 K	27.3 K	14.4 K	7.42 K	7.88 K	70.8 K	20.5 K	7.88 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.24 M	-998 K	696 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Akebia Therapeutics AKBA	58 K	$ 1.35	-2.17 %	$ 347 M	USA
Akari Therapeutics, Plc AKTX	100 K	$ 3.5	-21.7 %	$ 236 B	Britain
Aldeyra Therapeutics ALDX	1.69 M	$ 1.58	-4.82 %	$ 94.9 M	USA
Aligos Therapeutics ALGS	2.2 M	$ 8.36	4.89 %	$ 82.6 M	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 330.71	3.72 %	$ 43.3 B	USA
Altimmune ALT	-190 K	$ 3.47	3.89 %	$ 306 M	USA
ALX Oncology Holdings ALXO	1.6 M	$ 1.98	0.25 %	$ 106 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Amneal Pharmaceuticals AMRX	16.5 M	$ 12.37	-0.92 %	$ 3.88 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ANI Pharmaceuticals ANIP	-4.03 M	$ 76.34	2.87 %	$ 1.47 B	USA
Annexon ANNX	57 K	$ 5.64	2.45 %	$ 875 M	USA
Aprea Therapeutics APRE	634 K	$ 0.73	2.63 %	$ 4.77 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.15	0.48 %	$ 444 M	USA
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.43	4.98 %	$ 231 M	Israel
Ardelyx ARDX	4.5 M	$ 6.08	2.27 %	$ 1.47 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.93	1.27 %	$ 3.04 B	USA
Arvinas ARVN	-400 K	$ 11.11	2.4 %	$ 788 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Assembly Biosciences ASMB	117 K	$ 30.01	3.43 %	$ 336 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Actinium Pharmaceuticals ATNM	1.09 M	$ 1.14	16.28 %	$ 35.6 M	USA
Atossa Therapeutics ATOS	-6 K	$ 5.21	-2.89 %	$ 44.9 M	USA
Atara Biotherapeutics ATRA	3.79 M	$ 5.03	0.7 %	$ 63.1 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.42	0.35 %	$ 378 M	Britain
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA